Abstract
Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.
| Original language | English |
|---|---|
| Article number | e26855 |
| Journal | Pediatric Blood and Cancer |
| Volume | 65 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Oct 19 2017 |
Fingerprint
Keywords
- AIEOP LNH-97
- childhood
- NHL
- PMLBL
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
Cite this
Primary mediastinal large B-cell lymphoma : Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20. / Pillon, Marta; Carraro, E.; Mussolin, L.; Conter, V.; Tondo, A.; Aricò, M.; Mura, R.; Sala, A.; Vinti, L.; Buffardi, S.; Pierani, P.; d'Amore, E. S.G.; Basso, G.
In: Pediatric Blood and Cancer, Vol. 65, No. 2, e26855, 19.10.2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary mediastinal large B-cell lymphoma
T2 - Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20
AU - Pillon, Marta
AU - Carraro, E.
AU - Mussolin, L.
AU - Conter, V.
AU - Tondo, A.
AU - Aricò, M.
AU - Mura, R.
AU - Sala, A.
AU - Vinti, L.
AU - Buffardi, S.
AU - Pierani, P.
AU - d'Amore, E. S.G.
AU - Basso, G.
PY - 2017/10/19
Y1 - 2017/10/19
N2 - Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.
AB - Between 2007 and 2013, 13 children diagnosed with primary mediastinal large B-cell lymphoma (PMLBL) were treated according to a modified version of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) LNH-97 protocol based on high-dose methotrexate, anthracyclines, and addition of anti-CD20. Ten patients achieved a continuous complete remission with front-line therapy. The overall 5-year survival was 91.7%, and event-free survival was 83.9%, with only one patient dying of progressive disease. Despite the few cases, these results demonstrate that this therapy, which includes anti-CD20, given in a multicenter setting, is feasible with acceptable toxicity in children with PMLBL.
KW - AIEOP LNH-97
KW - childhood
KW - NHL
KW - PMLBL
UR - http://www.scopus.com/inward/record.url?scp=85038574577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038574577&partnerID=8YFLogxK
U2 - 10.1002/pbc.26855
DO - 10.1002/pbc.26855
M3 - Article
C2 - 29049862
AN - SCOPUS:85038574577
VL - 65
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 2
M1 - e26855
ER -